16^th International Conference on Pharmaceutical Formulations & Drug Delivery October 23-24, 2019 Amsterdam, Netherlands

DR. ALAIN L. FYMAT, BA, BS, MA, MS, PhD, PhD is a medical-physical scientist and an educator. He is the current President/CEO and Institute Professor at the International Institute of Medicine & Science with a previous appointment as Executive Vice President/Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was also Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science and an Advisor to the U.S. National Academy of Sciences, National Research Council, for postdoctoral programs tenable at the California Institute of Technology. He is Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and International Organizing Committee Member of several international scientific conferences. He has lectured extensively in the U.S., Europe, Asia and Africa. He has published ~ 425 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of 72 medical/scientific Journals to which he contributes regularly. Dr. Fymat is a Board member of several institutions, a professional member of the New York Academy of Sciences and the European Academy of Sciences, and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO. His current research interests are focused on neurodegenerative diseases (Alzheimer, Parkinson, epilepsy, dementias and others), oncology, molecular/precision/personalized medicine, and nanomedicine and nanobiotechnology.

Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine, nanomedicine and nanobiotechnology

Naji Najib has completed his Ph.D at the age of 28 years from Nottingham University and postdoctoral studies from College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, U.S.A and Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66044, U.S.A. He is the CEO of the International Pharmaceutical Research Center (IPRC), a Clinical Research Organization (CRO). He has published more than 100 papers in reputed journals and serving as an editorial board member of repute journals.

pharmaceutics, Pharmaceutical Chemistry and Clinical Research

Biography: Dr. Yavuz Selim Silay is the Co-Founder & CEO of MAIN(MaQasid Angel Investors Network) & chairman of Istanbul Consulting Group. MAIN(MaQasid Angel Investor Network) is one the fast growing global angel investment groups . ICG(Istanbul Consulting Group) which was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project.Yavuz is currently the Co-Founder of BioCube Ä°stanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Archem Diagnostics. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcilar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey.Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories

Research Interest: Interaction with FDA. Development of generic and branded regulatory strategic plans for new product development, life cycle management of marketed products. Evaluation of potential products & in-licensing opportunities. Participate in all aspects of clinical development & study management, providing scientific, medical, and logistical direction and support to studies.Clinical development in CNS/Pain Managing Phase 2-4 clinical trials